16-Hour Fast Supercharges Cancer Immunotherapy in Mice and Humans

Cancer immunotherapy has transformed oncology, yet many patients fail to respond adequately. Dietary interventions have long been proposed as adjuncts to treatment, but most require prolonged caloric restriction that proves difficult for patients — especially those already weakened by disease or therapy. This new study presents a compelling and clinically accessible alternative: a simple 16-hour fast.

Researchers from Zhejiang University School of Medicine conducted preclinical studies in mouse tumor models and clinical investigations in human cancer patients undergoing neoadjuvant immunotherapy. They examined how a transient 16-hour fast reshapes the tumor microenvironment (TME), particularly the metabolic crosstalk between cancer cells and immune cells.

The key mechanistic finding centers on isoleucine, a branched-chain amino acid. Short-term fasting caused isoleucine to accumulate within tumors. This intratumoral isoleucine surge reprogrammed CD8+ T cells — the frontline killers of the immune system — by altering their epigenetic landscape and remodeling phospholipids in cell membranes, ultimately enhancing their anti-tumor potency. In human patients, fasting prior to immunotherapy significantly boosted CD8+ T cell clonal expansion and cytotoxic gene programs, hallmarks of a stronger immune attack on tumors.

The findings suggest that brief fasting disrupts nutrient competition in the TME, shifting the metabolic advantage away from tumor cells and toward immune effectors. This creates a therapeutic window when immunotherapy can be most effective.

Clinically, this is promising because 16-hour fasting — essentially skipping one meal — is achievable and well-tolerated even in cancer patients. Caveats include that the mechanistic data are primarily from animal models, and larger randomized clinical trials are needed to confirm optimal timing, patient selection, and long-term safety before this becomes standard practice.